Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept and Proteasome Inhibitor Desensitization for Highly Sensitized Kidney Transplant Candidates
NCT05345717Phase 2Completed
- Sponsor
- University of Chicago
- Start
- May 2022
- Primary completion
- Sep 2025
- Modality
- Modified Peptides, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belatacept and bortezomib in Kidney disease, sponsored by University of Chicago. Primary endpoint: Likelihood of finding a donor to whom the study participant does not have strong anti-donor HLA specific antibodies (DSA) at 1 year. Started May 2022; status: completed.
02
Drugs
belataceptbortezomib
03
Conditions
Kidney disease
Beyond the preview
Go deeper on NCT05345717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345717.